Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Insider Sells $68,350.15 in Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) insider Greg Keenan sold 8,305 shares of the business’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $8.23, for a total value of $68,350.15. Following the completion of the transaction, the insider now directly owns 153,484 shares in the company, valued at approximately $1,263,173.32. This represents a 5.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Greg Keenan also recently made the following trade(s):

• On Monday, March 3rd, Greg Keenan sold 12,239 shares of Aurinia Pharmaceuticals stock. The stock was sold at an average price of $8.00, for a total value of $97,912.00.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH opened at $8.15 on Monday. The firm has a market cap of $1.12 billion, a PE ratio of -54.33 and a beta of 1.26. The stock’s fifty day moving average price is $8.08 and its two-hundred day moving average price is $7.89. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.67.

Institutional Trading of Aurinia Pharmaceuticals

Several hedge funds have recently made changes to their positions in AUPH. Tang Capital Management LLC raised its stake in shares of Aurinia Pharmaceuticals by 16.6% in the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company’s stock valued at $75,697,000 after buying an additional 1,200,000 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter valued at $9,662,000. Point72 Asset Management L.P. bought a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter valued at $7,630,000. Lazard Asset Management LLC raised its stake in shares of Aurinia Pharmaceuticals by 341.9% during the 4th quarter. Lazard Asset Management LLC now owns 596,389 shares of the biotechnology company’s stock valued at $5,355,000 after purchasing an additional 461,430 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Aurinia Pharmaceuticals during the 3rd quarter valued at $3,330,000. 36.83% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 19th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.